PATENT CLAIM ANALYSIS

Application Number: 15762602
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "062000"]

Abstract:
The present invention refers to a combination of hyaluronic acid, chondroitin sulfate in combination with at least one antacid agent, in particular magaldrate, for the prevention or treatment of gastric hyperacidity and gastroesophageal reflux and related pathologies thereof. More particularly, the combination is used for the preparation of oral compositions with at least one pharmaceutical carrier and advantageously that comprise a bioadhesive agent as well.

Claim (Index 4):
The combination according to  claim 2 , wherein it is a fixed combination wherein the sodium chondroitin sulfate is present 1.5 to 5 times in weight, and the magaldrate is present 3 to 20 times in weight, relative to the weight of sodium hyaluronate.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 1.39216
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14137493', '12991776', '09967977', '15105595', '13390084']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7780753653864458
- 35 USC 102 Novelty (BERT): 0.5172823944664411
- Combined Prediction Score: 0.7519960682944453
- Mean Citation Score: 245.46694
- Max Citation Score: 306.4786
- Similarity Product: 229.0902881117105

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test